- Home
- EDRY vs ALLK Comparison
EDRY vs ALLK Comparison
Compare EDRY & ALLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDRY
- ALLK
- Stock Information
- Founded
- EDRY 2018
- ALLK 2012
- Country
- EDRY Greece
- ALLK United States
- Employees
- EDRY N/A
- ALLK N/A
- Industry
- EDRY Marine Transportation
- ALLK Biotechnology: Pharmaceutical Preparations
- Sector
- EDRY Consumer Discretionary
- ALLK Health Care
- Exchange
- EDRY Nasdaq
- ALLK Nasdaq
- Market Cap
- EDRY 24.6M
- ALLK 29.5M
- IPO Year
- EDRY N/A
- ALLK 2018
- Fundamental
- Price
- EDRY $9.70
- ALLK $0.33
- Analyst Decision
- EDRY
- ALLK Hold
- Analyst Count
- EDRY 0
- ALLK 3
- Target Price
- EDRY N/A
- ALLK $2.00
- AVG Volume (30 Days)
- EDRY 3.1K
- ALLK 546.6K
- Earning Date
- EDRY 05-23-2025
- ALLK 05-27-2025
- Dividend Yield
- EDRY N/A
- ALLK N/A
- EPS Growth
- EDRY N/A
- ALLK N/A
- EPS
- EDRY N/A
- ALLK N/A
- Revenue
- EDRY $61,083,227.00
- ALLK N/A
- Revenue This Year
- EDRY N/A
- ALLK N/A
- Revenue Next Year
- EDRY $42.57
- ALLK N/A
- P/E Ratio
- EDRY N/A
- ALLK N/A
- Revenue Growth
- EDRY 28.35
- ALLK N/A
- 52 Week Low
- EDRY $8.00
- ALLK $0.22
- 52 Week High
- EDRY $24.84
- ALLK $1.56
- Technical
- Relative Strength Index (RSI)
- EDRY 58.49
- ALLK 61.39
- Support Level
- EDRY $8.78
- ALLK $0.32
- Resistance Level
- EDRY $8.85
- ALLK $0.33
- Average True Range (ATR)
- EDRY 0.19
- ALLK 0.00
- MACD
- EDRY 0.15
- ALLK -0.00
- Stochastic Oscillator
- EDRY 89.06
- ALLK 91.00
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulks such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers.
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation. Its portfolio consists of antibodies that target receptors, particularly Siglec-6, Siglec-8 and other anti-Siglec antibodies, including some antibodies in preclinical development.